SYDNEY, Australia, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 3344654) entitled “Anti-LAG-3 Antibodies” by the European Patent Office.
Original post:
Immutep Granted European Patent for IMP761
Recommendation and review posted by Fredricko
